Skip to main content
BoF Logo

Agenda-setting intelligence, analysis and advice for the global fashion community.

Zepbound Beats Wegovy in First Head-to-Head Trial

Eli Lilly’s GLP-1 drug Zepbound helped nearly 25 percent more participants lose weight than Novo Nordisk’s Wegovy, according to the trial results.
Wegovy injections
The findings come days after CVS Health’s decision to drop Zepbound from some lists of medicines it covers for reimbursement, instead favouring Wegovy. (Shutterstock)

Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk’s Wegovy across five weight-loss targets such as reducing waist circumference, citing data from a head-to-head trial.

Please sign in to ensure you can read our agenda-setting intelligence, analysis and advice. Or get in touch at support@businessoffashion.com if you experience difficulties.

In This Article
Organisations

© 2026 The Business of Fashion. All rights reserved. For more information read our Terms & Conditions

More from Beauty
Analysis and advice on the fast-evolving beauty business.
view more
Latest News & Analysis
Unrivalled, world class journalism across fashion, luxury and beauty industries.

The Industry That Eats Its Young

Small fashion labels have always been shortchanged by their wholesale partners. A wave of high-profile bankruptcies has turned a structural injustice into an existential crisis. There is a better way to do business, writes Imran Amed.


The Zara-Fication of John Galliano

Fashion’s enfant terrible is trading exclusivity for the mass market. Is it the ultimate fashion coup, or the final surrender of prestige?


The Impact of War on Fashion’s Supply Chain

Textile hubs are already feeling the cascading risks of the conflict in Iran as Washington ramps up forced labour probes to revive tariffs, while decarbonisation in fashion’s factories might finally have a standard to go off of.


VIEW MORE
Agenda-setting intelligence, analysis and advice for the global fashion community.
CONNECT WITH US ON